Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection.
OBJECTIVE
To review 10 years of experience providing fertility care to men seropositive for human immunodeficiency virus (HIV) using sperm washing and in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI).


METHODS
Retrospective study.


METHODS
University-based practice.


METHODS
HIV-seropositive men with HIV-seronegative partners.


METHODS
IVF-ICSI, HIV testing of females and infants.


METHODS
IVF performance, pregnancy rates, obstetrical outcomes, infection rates.


RESULTS
We initiated 420 cycles (355 fresh and 65 frozen cycles) in 181 couples. Due to poor ovarian response, 16% of stimulations were canceled. The number of oocytes collected per retrieval was 15.0 +/- 0.5, providing 12.1 +/- 0.5 mature oocytes suitable for ICSI, yielding 9.0 +/- 0.3 embryos per couple. The overall clinical pregnancy rate/embryo transfer was 45%; ongoing/delivered pregnancy rate/embryo transfer was 37%. The most frequent obstetric complication was multiple gestation (41%), with 5% experiencing high order multiple birth. An attendant high rate of preterm delivery was noted, as 43% of infants were born premature. No maternal or neonatal HIV infections or deaths occurred.


CONCLUSIONS
We have found IVF-ICSI to be an expeditious and safe means for HIV-serodiscordant couples to achieve pregnancy with minimal risk of viral infection. Risks and liabilities of IVF-ICSI relate to multiple gestations and will occur in a significant number of participants.
Sauer
Mark V
MV
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York 10019, USA. mvs9@columbia.edu
Wang
Jeff G
JG
Douglas
Nataki C
NC
Nakhuda
Gary S
GS
Vardhana
Pratibashri
P
Jovanovic
Vuk
V
Guarnaccia
Michael M
MM
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000502:physiology*; D005307:Fertilization in Vitro / Q000706:statistics & numerical data*; D005615:Freezing; D006679:HIV Seropositivity / Q000188:drug therapy / Q000503:physiopathology* / Q000635:transmission; D006467:Hemophilia A / Q000188:drug therapy / Q000453:epidemiology; D006509:Hepatitis B / Q000188:drug therapy / Q000453:epidemiology; D006526:Hepatitis C / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D050498:Live Birth / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D012189:Retrospective Studies; D020554:Sperm Injections, Intracytoplasmic / Q000706:statistics & numerical data*; D013094:Spermatozoa / Q000502:physiology*; D019562:Viral Load; D055815:Young Adult
D000998:Antiviral Agents